What PureIMS does

PureIMS B.V. is a privately held, clinical-stage pharmaceutical company headquartered in Roden, the Netherlands, founded in 2014 as a University of Groningen spin-off. The company develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, which is built around patented Air Classifier Technology that uses the patient's inhalation breath to disperse dry powder formulations into particles sized for deep lung deposition. PureIMS offers single-use (Cyclops® Classic) and multi-use (Cyclops® Switch and Cyclops® Charge) device variants, with high nominal dose capacity (5-100 mg), 90-100% drug loads, and fine particle fractions of 75-95%.

PureIMS's product pipeline includes Colistin Cyclops® (cystic fibrosis and bronchiectasis, granted EMA and FDA Orphan Drug Designation in December 2024), Levodopa Cyclops® (Parkinson's disease OFF episodes, pursuing 505(b)(2) pathway with demonstrated bioequivalence to Inbrija®), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® and Amikacin Cyclops® (pulmonary infections and tuberculosis), and inhaled cannabinoid products co-developed with Cannovex (Phase I planned for 2027). Colistin Cyclops® is currently the only commercially available product, distributed as a magistral/extemporaneous preparation in the Netherlands through Fagron and Infinity Pharma, with over 100,000 doses prescribed since 2015.

The company operates a sales-led, hybrid business model combining Dutch magistral product distribution with global licensing and co-development agreements to pharma and biotech partners. Revenue streams include hardware sales of magistral preparations, licensing and royalty agreements, outlicensing of internal pipeline assets, and venture/foundation funding (notably a 2023 round led by Boost-UP Foundation). PureIMS is preparing a Series A financing of approximately €20-25 million to advance lead programs to marketing authorization in the EU and US.

Name

PureIMS

Legal name

PureIMS B.V.

Website

https://pureims.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

PureIMS is a Dutch clinical-stage pharmaceutical company developing the proprietary Cyclops® dry powder inhaler platform for pulmonary delivery of therapeutics, serving cystic fibrosis, Parkinson's, anaphylaxis, and respiratory infection patients through licensing partners and Dutch magistral distribution.

Ownership category

akta.pro rank

Product category

Inhalation Pharmaceuticals / Dry Powder Inhaler Technology

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

akta.pro secondary industries

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

Keywords

• Dry powder inhalers
• Pulmonary drug delivery
• Inhalation therapeutics
• Pharmaceutical compounding
• DPI technology platform

Headquarters

HQ city

Roden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Named Patient/Magistral Use): Sales of Colistin Cyclops® as an extemporaneously produced (magistral) preparation in the Netherlands for cystic fibrosis and bronchiectasis patients. Product distributed through Fagron/Infinity Pharma partnership.
2. Licensing and Co-development Agreements: Revenue from partnering with pharma/biotech companies for development of Cyclops®-based inhalation products. Partners include Cannovex (cannabinoids), and others for antibiotics, vaccines, biologics, and other therapeutics.
3. Outlicensing of Pipeline Products: PureIMS maintains internal pipeline products (Levodopa Cyclops®, Epinephrine Cyclops®, Tobramycin Cyclops®, Amikacin Cyclops®) available for in-licensing to pharma partners.
4. Investment Funding: Venture capital and foundation funding to support clinical development of Cyclops® technology and pipeline products.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

PureIMS develops and commercializes the proprietary Cyclops® dry powder inhaler (DPI) platform, a pre-filled, breath-powered, credit card-sized inhaler using patented Air Classifier Technology for pulmonary drug delivery. The company sells Cyclops®-based products directly (Colistin Cyclops® as a magistral preparation in the Netherlands) and through co-development/licensing partnerships with pharma and biotech firms, building a pipeline across antibiotics (cystic fibrosis, bronchiectasis, tuberculosis), Parkinson's disease rescue therapy, anaphylaxis, and cannabinoid therapeutics.

Product overview

PureIMS offers the Cyclops® dry powder inhaler platform as its core technology, with multiple product variants (Cyclops®Classic for single-use, Cyclops®Switch and Cyclops®Charge for multi-use) and a portfolio of therapeutic applications. The product portfolio includes Colistin Cyclops® (cystic fibrosis/bronchiectasis, with EMA/FDA Orphan Drug Designation), Levodopa Cyclops® (Parkinson's disease OFF episodes, 505(b)(2) pathway), Epinephrine Cyclops® (anaphylaxis), Tobramycin Cyclops® (pulmonary infections), Amikacin Cyclops® (tuberculosis), and cannabinoid pharmaceuticals developed with partner Cannovex. The Cyclops® platform uses patented Air Classifier Technology for efficient dispersion with minimal excipients.

Differentiator

Problem solved

Functional benefit

Brands

• Colistin Cyclops: Pre-filled colistin dry powder inhaler for treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis.
• Levodopa Cyclops
• Epinephrine Cyclops
• Tobramycin Cyclops
• Amikacin Cyclops
• Cyclops Classic
• Cyclops Switch
• Cyclops Charge

Products and services

• Cyclops® Dry Powder Inhaler Platform Proprietary pre-filled, breath-powered dry powder inhaler platform using patented Air Classifier Technology to disperse dry powder formulations into small particles for deep lung deposition. Available in single-use (Cyclops® Classic) and multi-use versions (Cyclops® Switch and Cyclops® Charge). Delivers nominal doses of 5–100 mg with 90–100% drug loads, fine particle fractions of 75–95%, and 50–60% deep lung deposition. Used by PureIMS for its own pipeline and offered to pharma/biotech partners for co-development.
• Colistin Cyclops® Pre-filled colistin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Offers a patient-friendly alternative to nebulization with easy-to-use, pre-filled, and disposable design. Available as a magistral product in the Netherlands through Fagron/Infinity Pharma. Received EMA and FDA Orphan Drug Designation in late 2024.
• Levodopa Cyclops® Levodopa dry powder inhaler for fast and reliable relief of OFF episodes in Parkinson's disease. Provides faster onset of action and more flexible dosing than most other treatments. Demonstrated bioequivalence to Inbrija® in comparative PK studies. Pursuing a 505(b)(2) abbreviated regulatory pathway.
• Epinephrine Cyclops® Pre-loaded disposable breath-powered epinephrine dry powder inhaler for the fast and reliable treatment of allergies and impending anaphylaxis. Non-invasive, easy to handle, with fast onset of action. Credit card size for excellent portability. Designed as a more affordable, needle-free alternative to epinephrine auto-injectors.
• Tobramycin Cyclops® Tobramycin dry powder inhaler for the treatment of pulmonary Pseudomonas aeruginosa infections. Designed for use as part of continuous alternating therapy with inhaled colistin, offering patients the ease and comfort of Cyclops® throughout their treatment cycle.
• Amikacin Cyclops® Amikacin dry powder inhaler for the treatment of tuberculosis (TB) or non-tuberculous mycobacterial (NTM) infections. Aims to achieve higher amikacin concentrations in the lungs than conventional infusion or injection, potentially decreasing contagiousness more rapidly.
• Inhaled Cannabinoid Pharmaceuticals (Cyclops®) Inhaled pharmaceutical cannabinoid products developed through the strategic partnership with Cannovex. Combines Cannovex's proprietary cannabinoid formulations with PureIMS's Cyclops® DPI platform for pharmaceutical-grade development, targeting a range of active ingredients and indications.
• Cyclops® Classic (Single-Use DPI) Single-use dry powder inhaler model from the Cyclops® family, to be discarded after one use. Available in multiple colors and extensively tested with small molecule formulations, biologics, and vaccines with excellent results for dose emission and dispersion.
• Cyclops® Switch (Multi-Use DPI) Multi-use dry powder inhaler model with a non-removable slidable cartridge containing two separate pre-filled dose compartments. Can hold either one dose comprising two inhalations or two separate doses at different time points. Patent protected until 2043.
• Cyclops® Charge (Multi-Use DPI) Multi-use dry powder inhaler model allowing pre-filled cartridges with a single dose compartment to be easily replaced after emptying by inhalation. Suitable for weekly dosing regimens without the need for cleaning. Patent protected until 2043.

Quantifiable outcome

• Deep lung deposition estimated at 50-60% of nominal dose with fine particle fractions of 75-95%
• +6 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core, secondary and minor.

• CannovexcoreStrategic or Co-development Partner · 1 March 2026Strategic co-development partnership to develop pharmaceutical cannabinoid products using PureIMS's Cyclops® DPI. Cannovex holds exclusive rights for range of active ingredients and indications. Phase I clinical trials slated to begin in 2027. Validates versatility of Cyclops® platform.
• FagroncoreChannel Partner/ Reseller/ Distributor · 1 September 2024Fagron granted exclusive rights to organize national distribution of PureIMS's compounded preparations in the Netherlands including inhaled antibiotic for pulmonary Pseudomonas aeruginosa infections caused by cystic fibrosis. Fagron distributes through Infinity Pharma.
• Infinity PharmasecondaryChannel Partner/ Reseller/ Distributor · 1 September 2024Specializes in patient-specific drug compounding and equipped to provide active patient support. Manages dispensing of Cyclops® products nationwide in the Netherlands ensuring short delivery timeframes.
• University of GroningencoreStrategic or Co-development PartnerLong-standing academic collaboration with Department of Pharmaceutical Technology and Biopharmacy. Multiple scientific publications co-authored. Source of Cyclops® DPI technology origin.
• University Medical Center Groningen (UMCG)coreStrategic or Co-development PartnerCollaboration with Department of Lung Diseases and Tuberculosis, Department of Allergology, and Pediatric Pulmonology. Conducted clinical trials for Colistin Cyclops® and Amikacin Cyclops®.
• Harro Höfliger Verpackungsmaschinen GmbHsecondaryImplementation/ SI/ Consulting PartnerManufacturing equipment partner for scalable Cyclops® production. Published article on PureIMS in Harro Magazine. Strong partnerships with leading market-scale production line developers.
• Adjutec PharmaminorStrategic or Co-development PartnerCo-development partner pursuing pulmonary delivery of antibiotics using Cyclops® platform.
• Interventional Medical Device SolutionsminorStrategic or Co-development PartnerCollaboration partner listed on PureIMS website for various development projects.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Iconovo: Swedish clinical-stage company developing proprietary dry powder inhalers (ICOcap, ICOone, ICOres) for generic and novel inhaled therapeutics. Iconovo is the closest functional peer to PureIMS—same business model of providing a DPI platform for co-development and licensing with pharma partners, at a comparable early-stage scale.
• MannKind Corporation: US-listed company commercializing the Technosphere® breath-powered dry powder inhalation platform (Afrezza, V-Go, Tyvaso DPI after United Therapeutics licensing). MannKind is a direct platform peer—breath-powered DPI delivering high drug load to deep lung—and serves as a useful comparable for the licensing/royalty business model PureIMS is pursuing.
• Civitas Therapeutics / Acorda Therapeutics: Civitas developed the ARCUS® DPI platform used to deliver Inbrija® (inhaled levodopa) for Parkinson's disease OFF episodes—the very drug that PureIMS's Levodopa Cyclops® has demonstrated bioequivalence to. This makes Civitas/Acorda the single most direct competitive comparator for PureIMS's lead CNS program.
• Aradigm Corporation (Grifols): Aradigm developed the AERx® inhalation platform and led inhaled liposomal antibiotic programs (e.g., Linaprazid) targeting pulmonary infections including cystic fibrosis. It is a direct peer in the inhaled antibiotics space and was acquired by Grifols, illustrating one potential exit pathway for PureIMS.

Broad incumbents

• Vectura Group (Philip Morris International): Vectura is a long-established DPI/inhalation technology developer acquired by Philip Morris, offering formulation and device platforms (e.g., GyroHaler, LeverHaler, Fox) to pharma partners. It is a broader incumbent peer that validates the platform-licensing business model but operates at far greater scale and across more therapeutic areas.

Emerging players

• Pulmatrix: US clinical-stage company developing inhaled therapeutics using the iSPERSE® dry powder technology for respiratory diseases including cystic fibrosis and COPD. Pulmatrix is an emerging peer with overlapping indications (pulmonary infections) and a similar co-development/licensing go-to-market approach.
• Avalyn Pharma: US clinical-stage company developing inhaled therapies (e.g., AP01 for IPF) for pulmonary diseases. Avalyn is an emerging peer with overlapping inhaled-therapeutic positioning and similar phase-stage development, comparable as a fundraising and licensing comparable for PureIMS.
• Inhalon Biopharma: Clinical-stage biotech developing iSPERSE-based inhaled therapeutics for respiratory infections including COVID-19, influenza and cystic fibrosis. Inhalon is an emerging peer with overlapping pulmonary anti-infective focus and similar licensing-oriented business model.
• Respira Therapeutics: Early-stage company developing inhaled therapies for pulmonary and respiratory diseases, with focus on reformulating existing drugs for DPI delivery. Respira is an emerging peer in the same niche of using inhalation to improve established molecules.

Others

• Hovione: Portuguese CDMO with deep inhalation drug development and DPI manufacturing capabilities, partnering with pharma companies on inhaled formulations. Hovione is an adjacent enabling partner—PureIMS uses Harro Höfliger for production scaling, and Hovione represents a similar enabling-services peer in the inhalation CDMO ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCPAb5Hu1IHOSyg2holbHIJA
• LinkedInlinkedin.com/company/pureims/about

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PureIMS